SCHEMBL1623664

SCHEMBL1623664

Cc1ccc2c(N3CCCC(CNC(=O)O)C3)nc(-c3c(O)cccc3F)nc2c1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CHEK2 O96017 4/20 0.53
MAPT P10636 2/20 0.42
PPARA Q07869 3/20 0.39
GBA1 P04062 1/20 0.38
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
LMNA P02545 1/20 0.38
IRAK1 P51617 1/20 0.37
SMAD3 P84022 1/20 0.37
POLB P06746 1/20 0.36
P2RX3 P56373 2/20 0.36
P2RX2 Q9UBL9 1/20 0.36
HIF1A Q16665 1/20 0.36
CCNE2 O96020 1/20 0.35
CCNE1 P24864 1/20 0.35
CDK2 P24941 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1623660 1.00 CHEK2 (0.53) CHEK2MAPTPPARAGBA1ALDH1A1
Hydrochloric Acid SCHEMBL4020393 0.99 CHEK2 (0.53) CHEK2MAPTPPARAGBA1ALDH1A1
Hydrochloric Acid SCHEMBL4020411 0.99 CHEK2 (0.53) CHEK2MAPTPPARAGBA1ALDH1A1
SCHEMBL4015706 0.95 CHEK2 (0.57) CHEK2MAPTPPARAKDM4ELMNA
SCHEMBL4015696 0.95 CHEK2 (0.57) CHEK2MAPTPPARAKDM4ELMNA
SCHEMBL12721316 0.92 CHEK2 (0.48) CHEK2MAPTPPARAGBA1ALDH1A1
SCHEMBL12721320 0.89 CHEK2 (0.46) CHEK2MAPTPPARAGBA1ALDH1A1
SCHEMBL12721347 0.89 CHEK2 (0.46) CHEK2MAPTPPARAALDH1A1KDM4E
SCHEMBL1623522 0.88 CHEK2 (0.53) CHEK2MAPTGBA1IRAK1SMAD3
SCHEMBL1623519 0.88 CHEK2 (0.53) CHEK2MAPTGBA1IRAK1SMAD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8283354-B2 Voltage gated sodium and calcium channel inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-09 US disclosed
US-7928107-B2 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-04-19 US disclosed
US-20090312342-A1 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2009-12-17 US disclosed
EP-1784393-B1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMA (US) 2009-07-01 EP disclosed
EP-1784393-A1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS Vertex Pharmaceuticals Incorporated (US) 2007-05-16 EP disclosed
US-20060173018-A1 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2006-08-03 US disclosed
WO-2006028904-A9 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMA (US) 2006-06-22 WO disclosed
WO-2006028904-A1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312342-A1 Quinazolines useful as modulators of ion channels KCNQ1, KCNQ2, KCNN3 CHEK2 2935/4885MAPT 2508/4885PPARA 4093/4885
US-20060173018-A1 Quinazolines useful as modulators of ion channels KCNQ1, KCNQ2, KCNN3 CHEK2 2935/4885MAPT 2508/4885PPARA 4093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.